Specifically, insulin-sensitizing agents and inhibitors of insulin-like growth factor-1 receptor (IGF-1R) have been investigated as potential treatments for lung cancer, aiming to inhibit aberrant signaling and cell proliferation associated with insulin resistance. This evidence concerns the gene IGF1R and lung cancer.